Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Return on Sales (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Return on Sales for 5 consecutive years, with 336.03% as the latest value for Q4 2025.

  • Quarterly Return on Sales changed N/A to 336.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 336.03% through Dec 2025, changed N/A year-over-year, with the annual reading at 369.88% for FY2025, N/A changed from the prior year.
  • Return on Sales for Q4 2025 was 336.03% at Actinium Pharmaceuticals, down from 57.01% in the prior quarter.
  • The five-year high for Return on Sales was 5.49% in Q1 2022, with the low at 1063.44% in Q2 2023.
  • Average Return on Sales over 4 years is 228.58%, with a median of 115.73% recorded in 2022.
  • The sharpest move saw Return on Sales surged 31680bps in 2022, then tumbled -88900bps in 2023.
  • Over 4 years, Return on Sales stood at 349.91% in 2021, then skyrocketed by 91bps to 33.11% in 2022, then plummeted by -3112bps to 1063.44% in 2023, then soared by 68bps to 336.03% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 336.03%, 57.01%, and 1063.44% for Q4 2025, Q3 2025, and Q2 2023 respectively.